Company Overview
SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialisation of therapeutics, primarily first-in-class monoclonal antibody-based biologics, for the treatment of immunological diseases. The Company’s flagship product SM03 (Suciraslimab) is a global first-in-class anti-CD22 mAb for the treatment of rheumatoid arthritis (RA), is progressing at full speed towards its commercialisation. SM03 (Suciraslimab) has met its primary endpoint in its Phase III clinical study for the treatment of RA in China in April 2023. On 5 September 2023, the National Medical Products Administration of the People's Republic of China has accepted the biologics license application (BLA) for SM03 (Suciraslimab) in the treatment of RA. Clinical sites inspection and Good Manufacturing Practice (GMP) inspection at our Haikou production base, the two necessary procedures required as part of the BLA approval process, were completed in January 2024. In the meantime, we are continuing to advance clinical studies of Suciraslimab in other immunological diseases, including Alzheimer's disease and Sjogren's syndrome, to fulfill unmet medical needs and thus further promote the potential for subsequent commercialisation of the products.
Company Mission
We are the first Hong Kong-based listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics , primarily first-in-class monoclonal antibody (mAb) - based biologics, for the treatment of immunological diseases. Headquartered in Hong Kong, we strive to become a leading global biopharmaceutical company for the development of novel drugs to fulfill unmet medical needs through our Hong Kong-based innovative R&D, and PRC-based manufacturing capabilities. We have been dedicated to R&D since our inception, and have built a potential pipeline of mAb-based biologics and new chemical entities (NCE) addressing indications against a plethora of immunological diseases. SM03 (Suciraslimab), our flagship product, is a global first-in-class anti-CD22 mAb for the treatment of RA and other immunological and neuro-immunological diseases. Under the leadership of our management team, consisting of members with rich experience in scientific research and business management, we have established a business model that integrates elements from the entire industry chain encompassing R&D, clinical trials and production. Pursuant to this business model, we leverage our proven ability in novel drug discovery, clinical development and in-house manufacturing capabilities to enable multiple clinical trials and subsequent commercialisation. Our vision is to become a global leader in the innovation of therapeutics for immunological and other debilitating diseases.
